Breast Cancer Therapy Market is Estimated to be USD 63.13 Billion by 2032 with a CAGR of 8.5% | Polaris Market Research
September 13, 2024 08:00 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global breast cancer therapy market size is predicted to grow from USD 30.90 billion in 2023 to USD 63.13 billion by 2032....
Vidac Pharma publishes results of next-generation drug candidate tests in human and murine tumor models
July 25, 2024 01:30 ET
|
Vidac Pharma Holding PLC
London (UK), July 25, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel...
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
June 03, 2024 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new...
Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates
June 03, 2024 01:30 ET
|
Vidac Pharma Holding PLC
London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel...
Vidac Pharma annonce des données positives de l'analyse intermédiaire de phase 2a pour son produit phare VDA-1102 dans le traitement des Lymphomes T cutanés (LCT), une maladie rare.
January 29, 2024 02:00 ET
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 - Vidac Pharma Holdings Plc. (Hambourg et Stuttgart : T9G ; ISIN:GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, pionnière d'une...
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
January 29, 2024 02:00 ET
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking...
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
December 14, 2023 04:00 ET
|
AKAMPION
YONGIN, South Korea, December 14, 2023 – 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...
Vidac Pharma présente des résultats in vitro démontrant la compatibilité de VDA 1275 avec des agents chimiothérapeutiques classiques
November 29, 2023 01:00 ET
|
Vidac Pharma Holding PLC
Un nouveau régulateur du métabolisme des cellules cancéreuses bientôt à l’étude en vue d’une obtention d’une autorisation de mise sur le marché (IND) Londres (Royaume-Uni), Rehovot (Israël), 29...
Vidac Pharma reports in vitro results showing VDA-1275 compatible with classical chemotherapy
November 29, 2023 01:00 ET
|
Vidac Pharma Holding PLC
Novel cancer cell metabolism regulator to progress into IND enabling studies London (UK), Rehovot (Israel), 29 November 2023, 7:00 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G;...
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
November 13, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new...